Nanoparticles decorated with granulocyte-colony stimulating factor for targeting myeloid cells

Abstract

Nanoparticles target the protective shield of cancer, which consists of immunosuppressive myeloid cells.

Chemotactic NO/H2S Nanomotors Realizing Cardiac Targeting of G-CSF against Myocardial Ischemia-Reperfusion Injury

“…Table S3 summarizes the methods currently used to deliver G-CSF. For example, researchers have improved the half-life of G-CSF in the blood and reduced the number of doses administered by functionalizing it with PEG, PLGA, ,, or controlled the slow release of G-CSF using SiO 2 , dextran or BSA NPs as carriers. ,, On the one hand, none of the above delivery systems have attempted to deliver G-CSF to the heart site, and on the other hand, most of the carriers only play a single loading role and rarely involve microenvironmental modulation, making it difficult to use them directly for G-CSF delivery to the injured heart. With the SOD/PAC@CSF nanomotors, we delivered G-CSF precisely to the IRI site via a two-step targeting strategy.…”

“…In recent years, a variety of nanocarriers have been introduced to deliver G-CSF, such as the use of polymeric materials or bioderived exosomes to increase the half-life and stability of G-CSF in vivo , and the use of calcium carbonate and dextran nanoparticles to slowly release G-CSF for the treatment of neutropenia, leukemia, cancer, and other diseases to improve the bioavailability of G-CSF to some extent. − However, the specific location of the heart, with its systolic–diastolic dynamic activity accompanied by large changes in ventricular volume, triggers rapid and massive blood exchange, making it difficult for the drug to remain in the heart for long periods of time and much more difficult to accumulate at the site of IRI . Therefore, the above-mentioned delivery system for G-CSF cannot be directly applied to the treatment of IRI, and there is still a great challenge to develop a delivery system that can effectively achieve the effective aggregation of G-CSF at the site of IRI.…”

Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity

“…[ 118b ] Margulis and colleagues designed targeted fluorescent albumin nanoparticles to selectively label MDSCs, facilitating the monitoring of their integration into the TME. [ 86 ] Utilizing recombinant G‐CSF as a surface ligand, these nanoparticles predominantly accumulate in myeloid lineage cells, excluding other cells in the intricate TME. Further advancements may pave the way for diagnostic tracking of MDSCs and targeted delivery of therapies for MDSCs.…”

Leveraging Immunotherapy with Nanomedicine

“…[81][82][83] Similarly, granulocyte-colony stimulating factor (G-CSF) decoration of albumin NPs promotes preferential in vivo accumulation in MD-SCs in a 4T1 metastatic triple-negative breast mouse model. [84] This system could provide a cell lineage-specific delivery of indocyanine green, an effective photothermal and photosensitizing agent that can be used for MDSCs ablation in highly immunosuppressed patients. [85,86] In parallel, cancer cells upregulate CD47 that ligates with SIRP present on TAMs surface and eventually inhibit their phagocytic functions.…”